Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 800 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For... December 2, 2019 Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... June 15, 2022 Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... November 17, 2022 “After a fire and a pandemic, it felt amazing to finish... November 1, 2021 Load more HOT NEWS Radiotherapy Can Be Safely Omitted in Older Women with Low-Risk, HR-positive... What to Know About Mastectomy With Flat Closure After a Breast... Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among... Cleveland Clinic Launches Breast Cancer Vaccine Trial
